Multiple myeloma, the second most common hematologic malignancy, is characterized by the clonal expansion of plasma cells. Due to advances of new drugs and new therapies, the treatment of multiple myeloma patients has changed, and survival has become longer and longer. Therefore, chronic disease management model will become a new model for the treatment of multiple myeloma. In this review, we will discuss the concept of chronic disease management, the necessity, application, value, and benefit of chronic disease management in multiple myeloma.

1. 黄明安, 陈钰.慢性病管理研究进程的文献综述[J].当代经济, 2017(16): 142-144. DOI: 10.3969/j.issn.1007-9378.2017.16.054. [Huang MA, Chen Y. Literature review on the research process of chronic disease management [J]. Contemporary Economics, 2017(16): 142-144.] 

2. 田华, 李沭, 张相林. 慢病管理模式的国内外现状分析[J]. 中国药房, 2016, 27(32): 4465-4468. DOI: 10.6039/j.issn.1001-0408.2016.32.01. [Tian H, Li S, Zhang XL. Analysis of current situation of chronic disease man-agement model in the domestic and overseas[J]. China Pharmacy, 2016, 27(32): 4465-4468.]

3. 刘晓娜, 张华, 赵根明, 等. 我国慢性病预防与控制发展历程[J]. 公共卫生与预防医学, 2015, 26(2): 79-83. [Liu XN, Zhang H, Zhao GM, et al. Development of chronic disease prevention and control in China [J]. Journal of Public Health and Preventive Medicine, 2015, 26(2): 79-83.]

4. Mateos MV, San Miguel JF. Management of multiple myeloma in the newly diagnosed patient[J]. Hematology Am Soc Hematol Educ Program, 2017, 2017(1): 498-507. DOI: 10.1182/asheducation-2017.1.498.

5. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, et al. Global, Regional, and Na-tional Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016: A Systematic Analysis for the Global Burden of Disease Study[J]. JAMA Oncol, 2018, 4(11): 1553-1568. DOI: 10.1001/jamaoncol.2018.2706.

6. 赵蕴, 刘俊, 潘永卉, 等. 天津市多发性骨髓瘤患者住院费用影响因素分析[J]. 中国卫生产业, 2018, 15(19): 92-93. DOI: 10.16659/j.cnki.1672-5654.2018.19.092. [Zhao Y, liu J, Pan YH, et al. Analysis of factors in-fluencing hospitalization cost of multiple myeloma patients in Tianjin[J]. China Health Industry, 2018, 15(19): 92-93.]

7. 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会. 中国多发性骨髓瘤诊治指南(2017年修订)[J]. 中华内科杂志, 2017, 56(11): 866-870. DOI: 10.3760/cma.j.issn.0578- 1426.2017.11.021. [Chinese Hematology Association, Chinese Society of hematology, Chinese Myeloma Commit-tee-Chinese Hematology Association. The guidance for the diagnosis and man-agement of Multiple myeloma in China (2017 revision) [J]. Chinese Journal of Internal Medicine, 2017, 56(11): 866-870.]

8. Li J, Wang Y, Liu P. The impact on early diagnosis and survival outcome of M-protein screening-driven diagnos-tic approach to multiple myeloma in China: a cohort study[J]. J Cancer, 2019, 10(20): 4807-4813. DOI: 10.7150/jca.32103.

9. Zhao AL, Shen KN, Wang JN, et al. Early or deferred treatment of smoldering multiple myeloma: a me-ta-analysis on randomized controlled studies[J]. Cancer Manag Res, 2019, 11: 5599-5611. DOI: 10.2147/CMAR.S205623.

10  Tandon N, Sidana S, Rajkumar SV, et al. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma[J]. Blood Adv, 2019, 3(5): 744-750. DOI: 10.1182/bloodadvances.2018022806.

11.  Willenbacher W, Seeber A, Steiner N, et al. Towards molecular profiling in multiple myeloma: A literature re-view and early indications of its efficacy for informing treatment strategies[J]. Int J Mol Sci, 2018, 19(7): 2087. DOI: 10.3390/ijms19072087.

12.  Laubach J, Richardson P, Anderson K. Multiple myeloma[J]. Annu Rev Med, 2011, 62: 249-264. DOI: 10.1146/annurev-med-070209-175325.

13.  Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma[J]. N Engl J Med, 2016, 374(17): 1621-1634. DOI: 10.1056/NEJMoa1516282.

14.  Hou J, Jin J, Xu Y, et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus le-nalido-mide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study[J]. J Hematol Oncol, 2017, 10(1): 137. DOI: 10.1186/s13045-017-0501-4.

15.  Kumar SK, Buadi FK, LaPlant B, et al. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma[J]. Blood Cancer J, 2018, 8(8): 70. DOI: 10.1038/s41408-018-0106-3.

16.  王慧敏, 王润玲, 李素文, 等. 综合性医院多学科诊疗模式的实践与思考[J]. 中国农村卫生事业管理, 2019(10): 750-753. [Wang HM, Wang RL, Li SW, et al. Practice and thinking of multidisciplinary diagnosis and treatment model in general hospitals[J]. Chinese Rural Health Service Administration, 2019(10): 750-753.]

17.  黄蓓晖, 李娟, 刘俊茹, 等. 以硼替佐米为基础的诱导治疗后序贯自体造血干细胞移植治疗多发性骨髓瘤临床分析[J].中华内科杂志, 2014, 53(11): 865-872. DOI: 10.3760/cma.j.issn.0578-1426.2014.11.006. [Huang PH, Li J, Liu JR, et al. Clinical analysis of bortezomib induced sequential autologous hematopoietic stem cell transplantation for multiple myeloma[J]. Chinese Journal of Internal Medicine, ,2014, 53(11): 865-872.]

18.  咸玉萍. 自体外周血造血干细胞移植治疗多发性骨髓瘤的综合护理及临床效果观察[J]. 首都医药, 2019, 26(13): 122-123. DOI: 10.3969/j.issn.1005-8257.2019.13.104. [Xian YP. Comprehensive nursing care and clin-ical effect of autologous peripheral blood hematopoietic stem cell transplantation for multiple myeloma[J]. Capital Food Medi-cine, 2019, 26(13)122-123.]

19.  王欢, 周新, 朱健伟, 等. 初诊非造血干细胞移植的多发性骨髓瘤患者预后因素的长期回顾性分析[J]. 中国实验血液学杂志, 2019, 27(5): 1530-1539. DOI: 10.19746/j.cnki.issn1009-2137.2019.05.026. [Wang H, Zhou X, Zhu JW, et al. Long-term retrospective analysis of prognostic factors in patients with newly diagnosed multiple myeloma without hematopoietic stem cell transplantation[J]. Journal of Experimental Hematology, 2019, 27(5): 1530-1539.]

20.  闫苒. BD方案序贯自体造血干细胞移植及硼替佐米维持治疗多发性骨髓瘤的疗效分析[D]. 郑州大学, 2019. [Yan R. Analysis of the efficacy of BD induction regimen prior to autologous hematopoietic stem cell transplantation and bortezomib maintenance treatment in multiple myeloma[D]. Zhengzhou University, 2019.]

21.  马池. 电话随访式延伸护理服务在多发性骨髓瘤化疗患者中的应用观察[J]. 首都食品与医药, 2019, 26(24): 184-185. [Ma C. Application of extended care by telephone follow-up in patients with multiple mye-loma undergoing chemotherapy[J]. Capital Food Medicine, 2019, 26(24): 184-185.]

22.  国家医疗保障局. 《国家医疗保障局关于将17种抗癌药纳入国家基本医疗保险、工伤保险和生育保险药品目录乙类范围的通知》 [EB/OL]. (2018-10-10) [2020-02-26].  http://www.gov.cn/xinwen/2018-10/10/content_5328891.htm?tdsourcetag=s_pcqq_aiomsg. [National healthcare security administration. 17 cancer drugs added to insurance program list[EB/OL]. (2018-10-10) [2020-08-01]. http://www.gov.cn/xinwen/2018-10/10/content_5328891.htm?tdsourcetag=s_pcqq_aiomsg]

23.  杨娟, 杨燕凤, 杨婷, 等. 综合日常生活护理联合微信延续护理对骨髓瘤患者的影响[J]. 护理实践与研究，2019, 16(13): 82-84. DOI: 10.3969/j.issn.1672-9676.2019.13.034. [Yang J, Yang YF, Yang T, et al. Effect of integrated daily life nursing combined with WeChat continuous nursing on myeloma patients[J]. Nursing Prac-tice and Research, 2019, 16(13): 82-84.]

24.  汤志平. "互联网+"慢病管理的研究与应用[J]. 管理观察, 2018(31): 170-171. DOI: 10.3969/j.issn.1674-2877. 2018.31.067. [Tang ZP. Research and application of "Internet +" chronic disease management[J]. Management Observer, 2018(31): 170-171.]